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Dilemma of Cross-over Trials aND Their imPaCT oN BeNefiT 
assessmeNT iN oNCology
Ruof J.1, Staab T.R.1, Walter M.2
1Roche Pharma, Grenzach-Wyhlen, Germany, 2nspm ltd, Meggen, Switzerland
Objectives: Ethics committees often require cross-over design for highly sen-
sitive circumstances where it may be unethical to withhold active therapy. This 
can be the case particularly in oncology. Cross over can, however, dilute the treat-
ment effect seen in trial analyses. The German Institute for Quality and Efficiency 
in Health Care (IQWiG) follows distinct thresholds for comparative treatment 
effect, which it requires for a positive early benefit assessment (EBA) rating. The 
upper 95% confidence interval must be at least 0.85 to receive the highest rating. 
We evaluated if cross-over designs may negatively affect benefit assessment in 
Germany. MethOds: Oncology medicines that finished EBA procedures in Germany 
until June 2014 were evaluated for cross over in the manufacturer’s dossier. The 
extent of cross over on the observed treatment effects was investigated, as well 
as how the designs may affect the EBA ratings. Results: Ten out of 24 EBAs in 
oncology included assessment of trials with cross-over design. Cross over may have 
affected the observed treatment effects as demonstrated by a number of examples. 
Firstly, the proportion of patient cross over was as high as 62% for crizotinib. For van-
detanib, 12 out of 13 remissions in the control group could be attributed to a switch 
to active therapy. The hazard ratio for overall survival (OS) with vemurafenib versus 
dacarbazine was 0.37 without cross over at first data-cut in comparison to 0.62 with 
24% cross over at a later timepoint. These examples suggest that cross-over designs 
are both present in EBAs in oncology, and may affect the extent of comparative 
treatment effect. The affect of cross-over design was not systematically considered 
by IQWiG. cOnclusiOns: Cross-over design is an ethical necessity. However, it is 
known that these designs dilute treatment effect signals. German HTA EBAs need 
to improve in systematically accounting for such cross-over affects.
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reimBurseD PharmaCoTheraPy of meTasTaTiC Clear Cell KiDNey 
CaNCer (mCCKC) iN The CzeCh rePuBliC
Mazelova J., Slaby J.
State Institute for Drug Control, Prague, Czech Republic
Objectives: Concise analysis of reimbursement of drugs for mCCKC. Evaluation 
was performed from the aspect of the regulator; it regards drugs approved for use 
in outpatient care. The aim was to identify the development of criteria that must be 
met by reimbursed drugs, with regard to pharmacoeconomics and evidence-based 
medicine data. MethOds: We performed a search of the database of administrative 
proceedings (including proceedings on reimbursement determination as well as on 
reimbursement revisions) and detected those in which the Decision has already 
been made. Subsequently, an analysis of submitted evidence was carried out in 
cases where the reimbursement conditions were first set or amended. Results: 
Between Jan/2008 and Jun/2014, decisions were issued in 25 relevant proceedings 
regarding 9 drugs. Before 2008 (when the pricing and reimbursement decision com-
petence was transferred to the Institute) only interpheron-alpha (IFN) and inter-
leukin-2 (IL2) were reimbursed in this indication. The proceedings carried out by 
the Institute led in IFN and IL2 only to precision of the conditions to better reflect 
real clinical practice (obsolete regimens were left out). In IL2 the reimbursement 
conditions for the 1st line of treatment were extended to include the combination 
with bevacizumab (no pharmacoeconomics required as the evidence had already 
been assessed and relevant conditions approved for bevacizumab). For the other 
medicines, the reimbursement conditions were set or amended based on scientific 
evidence and pharmacoeconomics (1st line: sunitinib ICER/LYG: 25,9 t€ , sorafenib 
ICER/PFLY: 42,8 t€ , bevacizumab: 96,3 t€ ; 1st and 2nd line: pazopanib - CMA analysis 
vs. sunitinib; 2nd line: axitinib ICER/QALY 57,0 t€ , 2nd or 3rd line: everolimus: ICER 
per LYG: 6,9 t€ , ICER; temsirolimus: only costs per LYG: 13,7 t€ ). cOnclusiOns: 
Setting the reimbursement conditions depended not only on the submitted evi-
dence and pharmacoeconomic data but also on other elements (public interest, 
burden of the disease).
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reimBursemeNT of TargeTeD CaNCer TheraPies WiThiN Three DiffereNT 
euroPeaN healTh Care sysTems
Mihajlović J., Dolk C., Postma M.J.
University of Groningen, Groningen, The Netherlands
Objectives: To identify differences in the recommendations for targeted cancer 
therapies (TCT) in three distinctive European health care systems: Serbian, Scottish 
and Dutch, and to examine the role of cost effectiveness analyses (CEA) in such 
recommendations. MethOds: A list of currently approved TCTs cited from the 
European Medicines Agency (EMA) was cross-referenced with the drug reimburse-
ment reports issued by Health Insurance Fund (RFZO) for Serbia, Scottish Medicines 
Consortium (SMC) for Scotland and Health Institute (ZI) for the Netherlands. The 
following key variables were gathered from the reports: drug indication, registra-
tion status, reimbursement status and outcome of the cost effectiveness evalu-
ation. Results: There were 44 TCTs indicated for 75 cancer sites and approved 
by EMA. Out of total number of drugs per indication (d/i= 75), 20 were reimbursed 
in Serbia, and 15 are still without the decision from RFZO. Remaining majority of 
TCTs is not registered in Serbia. None of submissions neither CEAs were publically 
available. SMC positively assessed 25 d/i and rejected as much as 30. All apprais-
als were published, and majority contained full CEAs. Finally, Dutch ZI accepted 
total of 59 d/i and disapproved use of only 5 d/i. The majority of reimbursed drugs 
were exempted from CEA in accordance with the policy for expensive hospital 
drugs. cOnclusiOns: Although data collected for Serbia did not allow us to evalu-
ate practiced policy in broader extent, it is certainly surrounding with the smallest 
number of reimbursed TCTs. Surprisingly, TCTs in Scotland were comparable to 
this number, yet reasons for such an outcome were fairly different. It seems that 
full application of CEA in TCTs submission contributed to 55% of SMC negative 
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Objectives: FN is a cost-intensive complication of chemotherapy. The study aimed to 
describe HCRU in hospitalized FN patients in BG, CZ and SK. MethOds: Multicentre 
international, retrospective, observational study in adult patients, who received the 
chemotherapy leading to the first (= index) FN event between 01/2009 and 09/2012. 
FN-specific HCRU parameters included infection prophylaxis and treatments, G-CSF 
use, other prophylactic medication, specific interventions and investigations, and 
FN-related hospitalizations. Unless otherwise stated, country data are reported in 
the order BG–CZ–SK. Results: 314 patients (156, 79, 79) with a median age of 55.5, 
56.0, and 57.0 years, and mostly ECOG status 0-2 (81%, 100%, 91%) were analysed. Most 
frequent STs and HMs were breast cancer (23% BG; 24% SK), testicular cancer (28% CZ); 
acute myeloid leukemia (29% BG), non-follicular lymphoma (31% CZ; 33% SK). G-CSF 
was used in the index cycle by 92%, 91%, and 68% of patients, usually as treatment 
(64%, 27%, 57%) rather than primary prophylaxis (20%, 41%, 8%). Most patients had one 
FN episode (88%, 96%, 94%), mostly in cycle 1 (56%; 72%; 58%). The mean (SD) number 
of FN-related hospital days was 7.2 (4.78), 7.2 (6.04), and 9.2 (5.12), with generally 
longer stays in HM than ST patients. The number of FN-related investigations in the 
index cycle were 531 in 125 patients (80%), 496 (49; 62%), and 585 (66; 84%); FN-related 
interventions: 416 (109; 70%), 328 (46; 58%), and 473 (55; 70%), respectively. The most 
frequent investigations were blood tests; the most frequent interventions were IV 
fluids and blood transfusions. Anti-infectives were frequently administered in the 
index cycle (72%, 98%, 99%). G-CSF use, FN-related investigations, interventions and 
anti-infective use continued in subsequent cycles. cOnclusiOns: Results indicate 
considerable HCRU in patients experiencing FN in all countries. Frequent lack of G-CSF 
primary prophylaxis was observed, particularly in SK.
PCN246
aWareNess of BreasT CaNCer aND iTs PreveNTioN. a ComParaTive 
survey amoNg fiNNish aND huNgariaN WomeN
Érsek K., Nagy B.
Healthware Consulting Ltd., Budapest, Hungary
bAckgROund: Finland has more favourable profile in breast cancer statistics 
compared to Hungary, along with an almost double participation rate in screening 
examinations. However, regarding medical practice and access to latest treatment 
only minor differences exist. Main hypothesis of the research was that awareness, 
knowledge and therefore better attitude towards breast cancer screening explains 
the difference in primary prevention’s efficiency. Objectives: The aim of the ques-
tionnaire survey was to assess what extent women are aware of the prevention 
opportunities in their home country as well as being aware of risk factors of breast 
cancer; furthermore what impact does it have on their behaviour how they assess 
their own general health status and risk of cancer. MethOds: A web-based ques-
tionnaire survey was carried out in 2013-2014 among adult women. Demographic 
characteristics, lifestyle, general and cancer-specific health status (including per-
sonal and family history of breast cancer), knowledge and experience with primary 
prevention were covered. An internationally utilized medical risk calculator was 
included in the questionnaire for classifying responders based on their calculated 
risk of breast cancer, as well as to compare those to the risk assumed by them-
selves. Results: More than 400 participants were involved in the survey from the 
two countries. There were no significant differences identified in the acknowledged 
personal and family health background. Main difference was in the participation 
inclination in screening. Source of getting information means a major impact on 
prevention-related behaviour. Formal education and informing by medical staff 
were the most effective, however magnitude of uncontrolled ‘self-education’ via 
internet and social media is increasing with a potential biasing impact on knowl-
edge. cOnclusiOns: Survey results suggest that utilizing participation ratio in 
comparative screening assessment as a key parameter. Results indicate that partici-
pation can be influenced by increasing efficiency of information flow, with proper 
education as one of the main intervention opportunities.
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liKely imPaCT of NeT PriCe refereNCiNg oN euroPeaN marKeTs
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likely impact of Net Price referencing on european markets Patel P1, Ladrón de 
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Objectives: With the introduction of new pricing measures in countries such as 
Germany, the visibility of net pharmaceutical product prices (prices with a manda-
tory rebate) could soon become a requirement. Three European markets that cur-
rently employ rebates are Germany, Spain and Italy. The objective of this study is 
to map out likely consequences of International Price Referencing (IRP) using net 
prices on three products; Avastin, Caprelsa and Vidaza. MethOds: Using data from 
PRICENTRIC, we collected net and list ex-factory prices for Avastin, Caprelsa and 
Vidaza across EU-28. Countries that do not use formal IRP as a price setting mecha-
nism were excluded from the analysis, countries that consider price reviews were 
included. Projected prices were calculated using country IRP rules and exchange 
rates from the European Central Bank. The current approved prices were compared 
to the likely projected prices. The analysis investigated two key areas: 1. Countries 
impacted 2. Potential price impact. Results: Figure 1 shows the current prices for 
the 3 products. Figure 2 illustrates the countries impacted by the change and likely 
price points. One of the first countries affected would be Netherlands (Netherlands 
reviews prices every 6 months), followed closely by Switzerland and Ireland. The 
potential impact could range from price reductions of 9.69% for Vidaza in Ireland to 
30.77% for Avastin in Switzerland. cOnclusiOns: The trend for net price referenc-
ing has already been adopted by Greece since February 2014 where Greece moved 
from referencing the Italian list price to the net price. The concern for industry if 
this were to become the norm for other markets and if net prices were to become 
publically visible, substantial price reductions could be on the horizon.
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by G-BA, due to the high methodological standards set by G-BA and IQWiG, manu-
facturers should de-prioritize this endpoint.
PCN254
meDia Coverage of The NiCe firsT DrafT CoNsulTaTioN guiDaNCe for 
TrasTuzumaB emaNTaNsiNe (KaDCyla) iN BreasT CaNCer
Macaulay R.
HERON Commercialization, London, UK
Objectives: The National Institute of Health and Care Excellence (NICE) makes 
recommendations on which drugs the National Health Service (NHS) should fund, 
with cost-effectiveness being a key criterion. There have been critical media reac-
tions toward NICE appraisals that recommend against funding drugs (particularly 
oncologics), perhaps the most memorable example of which relates to the funding 
of Herceptin in early-stage breast cancer in 2005. This research aimed to evaluate 
how the media currently report NICE decision-making, focussing on the NICE 
appraisal consultation document not recommending Kadcyla on 23rdApril 2014 
with a cost per Quality Added Life Year (QALY) > £180,000, far exceeding typical 
NICE approval thresholds (~£30,000/QALY). MethOds: A selection of national and 
regional newspaper websites, UK broadcasters, press agencies, pharmaceutical 
trade and medical publications were screened for any articles published between 
23rd-25thApril 2014 regarding this NICE draft guidance from which key criteria 
were extracted and compared. Results: 19 articles were extracted (6 national 
newspapers, 6 regional newspapers, 3 broadcasters, and 4 other). 7/19 articles 
primarily focussed on the reaction of a patient/doctor, all of whom were particu-
larly critical of the NICE decision. 3/19 focussed on the high proposed cost of the 
new drug, 2 of which were critical of the pharmaceutical company. 9/19 followed 
the format of briefly summarising the decision and drug, with the majority of 
the article comprising reactions from various sources. However, there was an 
overall numerically higher number of sources in each article criticizing NICE (38, 
mean 2.0 per article) than those defending the NICE decision (21, mean 1.1 per 
article). cOnclusiOns: NICE decisions not to fund oncology drugs still seem to 
be predominantly faced by a hostile media reception that focus more on patient 
reactions than the difficulties of how to allocate finite health care resources to 
best optimise care in the NHS.
PCN255
ComPariNg hoW siNgle arm Phase ii Trial DaTa CaN suPPorT aPProval 
of oNCologiCs By euroPeaN healTh TeChNology assessmeNT BoDies
Macaulay R.
HERON Commercialization, London, UK
Objectives: The European Medicines Agency (EMA) approved 15 oncologics across 
24 indications based on pivotal single-arm Phase II data (Macaulay, ISPOR Dublin 
2013). Approval was typically granted for indications in which there was no thera-
peutic alternative where a response rate of ≥ 35% was demonstrated. This research 
aims to compare how such data can further support approval between different 
European Health Technology Agencies (HTAs). MethOds: Relevant National 
Institute of Health and Care Excellence (NICE), Scottish Medicines Commission 
(SMC), Commission de la Transparence (CT), Institute for Quality and Efficiency 
in Health Care (IQWiG), Federal Joint Committee (G-BA), and Swedish Dental and 
Pharmaceutical Benefits Agency (TLV) reports were sourced for any oncologic 
approved by the EMA on the basis of pivotal Phase II data (up to March 2014) and 
the decision and key rationale were analysed. Results: CT fully reimbursed 14/14 
(100%) oncologics appraised on the basis of pivotal Phase II data, with 10/14 obtain-
ing ASMRs I-III. In Germany (IQWiG), 6/6 (100%) oncologics appraised on this basis 
were deemed to offer some added benefit, avoiding reference pricing (5/6 were 
orphan drugs which are not subject to a benefit assessment). NICE approved 5/7 
(71%), SMC 6/11 (55%), and TLV 7/7 (100%) of oncologics appraised on Phase II data. 
For NICE/SMC/TLV rejected drugs, the clinical case was not strongly criticised, rather 
cost-utility values were deemed too high and uncertain. Even for approved drugs, 
the lack of comparative data was critiqued as introducing considerable uncertainty 
to submissions. cOnclusiOns: For any oncologic approved by the EMA on the basis 
of Phase II data, favourable ASMR and benefit ratings can be awarded on this basis 
by the CT and IQWiG/G-BA, respectively. NICE, SMC, and TLV recommendations are 
conditional on cost-effectiveness being adequately demonstrated with additional 
price discounts required to offset inherent uncertainties in cost-utility modelling 
from such limited clinical data.
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ComPariNg aCCess To Drugs Through The CDf aND By NiCe – The CDf 
sTiPulaTe sTriCTer CliNiCal CriTeria BuT Will also aPProve fuNDiNg 
for off-laBel usage
Macaulay R.
HERON Commercialization, London, UK
Objectives: The Cancer Drugs Fund (CDF) was set up in 2011 in England to enable 
cancer patients to gain access to therapies that are not routinely available on the 
NHS. However, this fund has been criticised for providing funding for therapies 
that have not been shown to be cost-effective by the National Institute for Health 
and Care Excellence (NICE). This research aims to define how restrictive criteria 
are for accessing drugs under the CDF and how this compares to access under 
NICE. MethOds: A systematic review of the criteria for accessing drugs accord-
ing to the national CDF list was undertaken and was compared to NICE-published 
statistics for oncology technology appraisals up to 31st March 2014. Results: 
80 oncologic indications have been approved under the CDF, each with specific criteria 
for access and usage. Overall, an average of 5.0 (range 3-11) criteria were specified for 
each drug. Typically, 3 criteria were specified for all drugs: 1) consultant specialist pre-
scriber; 2) specifying the disease; and 3) the line of therapy. However, many agents had 
additional restrictions on top of this, including 20/80 (25%) specifying the performance 
status (14 had 0-1; 6 had 0-2) and 12/80 (15%) to be used within the treating Trust’s 
governance framework as these drugs were not licensed in the specified indication. 
recommendations. Its Dutch counterpart, ZI, issued only 8% of negative decisions 
to TCTs. The mode for a success rate in the Netherlands was special policy that 
enabled reimbursement of TCTs without CEA.
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The CaNCer Drugs fuND: a sysTemaTiC aNalysis of The requiremeNTs 
for iNClusioN oN The eNglish NaTioNal lisT of Drugs for PrioriTy 
fuNDiNg
Macaulay R.
HERON Commercialization, London, UK
Objectives: The Cancer Drugs Fund (CDF) was set up in 2011 in England to enable 
patients to access therapies that are not routinely available on the National Health 
Service (NHS). In April 2013, NHS England became responsible for the management 
of the CDF with a single national list of drugs for prioritised funding. As the CDF 
has recently been extended to 2016, it is increasingly important to understand 
the key criteria for inclusion on the CDF-approved list, which this research aims 
to define. MethOds: CDF appraisal reports were sourced from the NHS England 
website (April 2013 – March 2014) and the date, decision, and key rationale were 
extracted. Results: 56 CDF decision summaries were available, 14 (25%) received 
full approval, 10 (18%) received conditional/restricted approval, 28 (50%) were 
rejected, and 4 (7%) were referred to commissioning. The key clinical attributes 
of each oncologic were given a numerical scoring that sum to a possible maxi-
mum +21 and minimum -4. The maximum score of any drug appraised was +8 
and the minimum was -1. Excluding appraisals referred to commissioning, 16/18 
appraisals scoring < 2 were rejected (89%) compared to only 5/25 (20%) scoring > = 2 
(4/5 primarily due to trial comparator choice). 9 were not scored due to a lack of 
appropriate evidence. 11 submissions were only based on Phase II data (for such 
submissions, efficacy scores were halved), 5 of which were approved. cOnclusiOns: 
A score of > = 2 seems to be the key clinical threshold above which most 
drugs are CDF-approved, below which most are rejected. Given that 43/47 scoring 
drugs scored -1 for toxicity, this means that 3 points are typically required, which 
can come through a 4-5 month Progression Free Survival or Overall Survival gain (or 
a 2-3 month gain in both), but this must be versus the clinically relevant comparator.
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TesTiNg The uTiliTy of The Nhs’s sysTemiC aNTi-CaNCer TheraPy DaTa 
seT for mulTi-iNDiCaTioN PriCiNg
McNamara L., McNamara S.
Roche Products Ltd., Welwyn Garden City, UK
Objectives: The price of a medicine should reflect the value it offers to patients, 
the health care system and society more broadly. However, with current pricing 
manufacturers can only set the price of a product based upon the cost per unit of 
that product. This may result in a price being set which society considers as being as 
‘too high’ in certain indications. This apparent mismatch in value and cost can lead 
to patients being denied access to medicine in certain indications. MethOds: The 
implementation of a pricing model where there is differentiated value of a medi-
cine across indications, line of therapy or if used as a mono/combination therapy 
requires the use of real world drug utilisation data. The Personalised Reimbursement 
Models project is at the forefront of the development and implementation of innova-
tive pricing approaches in the UK. This project includes identifying and developing 
the infrastructure required in order to introduce Multi-Indication Pricing (MIP) into 
the NHS in the UK. We have worked alongside NHS Trusts and national bodies in 
a joint working project to validate and test the utility of the Systemic Anti-Cancer 
Therapy (SACT) dataset. Results: This joint working project demonstrates that 
SACT has the potential to allow implementation of MIP in England. cOnclusiOns: 
Following completion of this work we hope SACT will be used to introduce MIP in 
England - this will eliminate the administrative pharmacy burden of data collection 
for commercial schemes for cancer medicines, enabling medicines to be priced 
for the value they provide in each of their uses and ensure that patients are not 
disadvantaged due to having a condition potentially treatable by a product with 
multiple indications.
PCN253
oNCology ProDuCTs iN The amNog ProCess – learNiNgs for a 
suCCessful Dossier suBmissioN
Dehnen J., Goldhagen K.
IMS Consulting Group, Muenchen, Germany
Objectives: Since AMNOG reform has taken effect 3.5 years ago, 78 dossiers have 
been evaluated by the G-BA. Especially with oncology agents, 28 products have 
started the process and G-BA has finalized decisions for 25 dossiers. In 20 cases addi-
tional benefit was granted. Therefore, the success rate of oncology products is 80% 
and much higher than the success rate of non-oncology products (29%). MethOds: 
An analysis of all oncology assessments will reveal key drivers responsible for the 
positive assessments by IQWiG and G-BA. Beside the study design (H2H vs. indirect 
comparison), and comparator choice the analysis will focus on submitted end-
points. It will be evaluated which endpoints contribute most in oncology indications 
to additional benefit. Results: Additional benefit is assessed based on patient 
relevant endpoints (mortality, morbidity, quality of life & safety). More than 55% 
of submitted endpoints fall in the safety category, followed by morbidity (approx. 
30%), mortality (approx. 10%) and quality of life (approx. 5%). The most important 
endpoint is mortality (OS), where the G-BA granted additional benefit in 18 out 
of 20 dossiers primarily based on OS data. In terms of morbidity, PFS, ORR and 
“Time to Pain Progression” are the top three most submitted morbidity endpoints; 
however, only “Time to Pain Progression” led to additional benefit in 2 out of 3 
cases. Only in one case quality of life contributed to the overall additional benefit 
decision. cOnclusiOns: OS will continue to be the most additional benefit con-
tributing endpoint in oncology. In the absence of OS, PFS will not help in the overall 
additional benefit decision by G-BA, unless the MNF can justify PSF to be patient 
relevant according to IQWiG methodology. Although QoL is an accepted endpoint 
